Discovery Labs (DSCO) resumes trading, with shares +26.7% AH following FDA approval of Surfaxin....

|By:, SA News Editor

Discovery Labs (DSCO) resumes trading, with shares +26.7% AH following FDA approval of Surfaxin. Shares spiked as high as $6.85 on resumption but have since pulled back to ~$3.75.